A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil®in 9-15-Year-Old Girls.
- Vesikari, Timo
- Brodszki, Nicholas
- van Damme, Pierre
- Diez-Domingo, Javier
- Icardi, Giancarlo
- Kjeld Petersen, Lone
- Tran, Clément
- Thomas, Stéphane
- Luxembourg, Alain
- Baudin, Martine
Publication date
January 2015
DOI Publisher
Ovid Technologies (Wolters Kluwer Health)Abstract
A 9-valent human papillomavirus (9vHPV) vaccine has been developedto prevent infections and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV [qHPV] vaccine), as well as 5additional oncogenic HPV types (HPV 31/33/45/52/58). Compared with the qHPV vaccine, the 9vHPV vaccine potentially increases the coverage of protection from 70% to 90% of cervical cancers. We compared the immunogenicity and safety of the 9vHPV vaccine vs. the qHPV vaccine in 9-15-year-old girls
Add to ORKG